Table 3.
Hazard ratios for inflammatory breast cancer patient mortality based on patient characteristics, Patterns of Care Study, 2004–2012.
| Characteristic | At risk | Cause of death | ||||
|---|---|---|---|---|---|---|
| Breast cancer | Any cause | |||||
| Number | %∗ | Number of deaths | HR (95% CI)∗∗ | Number of deaths | HR (95% CI)∗∗ | |
| Total | 170 | 91 | 121 | |||
| Age at diagnosis, years | ||||||
| <50 | 50 | 26.4 | 25 | 1 (ref.) | 30 | 1 (ref.) |
| 50–59 | 49 | 34.1 | 31 | 2.05 (1.03–4.08) | 37 | 1.89 (1.03–3.47) |
| 60–69 | 36 | 22.6 | 18 | 1.15 (0.48–2.74) | 24 | 1.28 (0.65–2.53) |
| ≥70 | 35 | 16.9 | 17 | 1.92 (0.81–4.56) | 30 | 2.53 (1.34–4.77) |
| Ancestry/ethnicity | ||||||
| European, non-Hispanic | 81 | 68.4 | 36 | 1 (ref.) | 48 | 1 (ref.) |
| African, non-Hispanic | 68 | 22.4 | 43 | 1.76 (1.05–2.97) | 56 | 1.86 (1.19–2.91) |
| Hispanic | 14 | 7.6 | 8 | 1.14 (0.35–3.71) | 11 | 1.57 (0.72–3.40) |
| Other | 7 | 1.6 | 4 | 1.25 (0.67–2.33) | 6 | 1.66 (0.88–3.13) |
| Piccirillo Comorbidity Score | ||||||
| None | 55 | 33.0 | 26 | 1 (ref.) | 35 | 1 (ref.) |
| Mild | 68 | 40.6 | 38 | 0.55 (0.27–1.12) | 48 | 0.48 (0.27–0.87) |
| Moderate | 29 | 17.0 | 14 | 1.01 (0.43–2.41) | 21 | 0.86 (0.39–1.86) |
| Severe | 16 | 7.9 | 13 | 2.77 (1.35–5.69) | 16 | 2.64 (1.32–5.27) |
| Unknown | 2 | 1.6 | 0 | — | 1 | 0.88 (0.44–1.75) |
| Metastasis on presentation | ||||||
| Yes | 63 | 31.1 | 49 | 3.20 (1.87–5.48) | 59 | 2.97 (1.86–4.73) |
| No | 107 | 68.9 | 42 | 1 (ref.) | 62 | 1 (ref.) |
| ER/PR status | ||||||
| ER+ and/or PR+ | 87 | 49.1 | 38 | 0.55 (0.29–1.03) | 56 | 0.54 (0.32–0.92) |
| ER− and PR− | 70 | 42.9 | 45 | 1 (ref.) | 54 | 1 (ref.) |
| Unknown | 13 | 8.1 | 8 | 2.11 (0.76–5.83) | 11 | 1.89 (0.71–5.05) |
| HER2 status | ||||||
| Positive | 62 | 35.9 | 33 | 0.74 (0.40–1.36) | 42 | 0.90 (0.55–1.49) |
| Negative | 83 | 48.2 | 45 | 1 (ref.) | 61 | 1 (ref.) |
| Unknown | 25 | 16.0 | 13 | 0.84 (0.19–3.70) | 18 | 0.80 (0.21–3.07) |
| Grade | ||||||
| Well or moderately differentiated | 31 | 22.4 | 13 | 1 (ref.) | 21 | 1 (ref.) |
| Poorly differentiated | 112 | 66.0 | 64 | 1.84 (0.72–4.71) | 84 | 1.83 (0.91–3.69) |
| Undifferentiated | 6 | 1.8 | 2 | 0.46 (0.05–3.91) | 2 | 0.38 (0.05–2.81) |
| Unknown | 21 | 9.9 | 12 | 1.12 (0.39–3.20) | 14 | 0.84 (0.36–1.96) |
ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; ref., reference group. ∗Percentages weighted based on sampling design. ∗∗Cox proportional hazards models adjusted for age, metastasis on presentation, ER/PR status, treatment, and sampling weights and strata within each study center.